Complement C3/C3a/C3a Des-Arg 抗体
适用: 人
IA, FACS, WB
宿主: 小鼠
Monoclonal
2898
unconjugated
(2 references)-
- 抗原
- Complement C3/C3a/C3a Des-Arg
- 适用
- 人
- 宿主
- 小鼠
- 克隆类型
- 单克隆
- 应用范围
- Immunoassay (IA), Flow Cytometry (FACS), Western Blotting (WB)
- 过滤
- 0.2 μm filtered
- 克隆位点
- 2898
-
- 应用备注
- For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Positive Human plasma control Negative C3-depleted serum control 1
- 限制
- 仅限研究用
-
- 缓冲液
- PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
-
-
: "Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles." in: Thrombosis and haemostasis, Vol. 97, Issue 1, pp. 67-80, (2007) (PubMed).
: "Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures." in: Journal of immunological methods, Vol. 166, Issue 1, pp. 35-44, (1993) (PubMed).
-
: "Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles." in: Thrombosis and haemostasis, Vol. 97, Issue 1, pp. 67-80, (2007) (PubMed).
-
- 抗原
- Complement C3/C3a/C3a Des-Arg
- 背景
- The monoclonal antibody 2898 recognizes the C-terminus of human complement protein C3a. The antibody recognizes intact C3, C3a as well as C3a-desArg. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. The complement system is an important part of the humoral response in innate immunity, consisting of three different pathways. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 releasing C3a anaphylatoxin and C3b. C3a is a protein of 74 amino acids. C3a itself is very short-lived and in serum is cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP). Therefore, measurement of C3a-desArg allows reliable conclusions about the level of complement activation in the test samples. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. Aliases Complement protein C3 Immunogen Peptide CARASHLGLA (last nine amino acids of C3a-desArg)
-
You are here:
